Afya Limited (NASDAQ:AFYA) Stock Short Interest Report for October

Afya Limited (NASDAQ:AFYA) was the target of a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 436,997 shares, a drop of 78.5% from the September 30th total of 2,033,841 shares. Based on an average trading volume of 505,835 shares, the short-interest ratio is presently 0.9 days. Approximately 0.5% of the company’s shares are short sold.

Analyst Ratings Changes

Several research firms have commented on AFYA. Bradesco Corretora raised Afya to an “outperform” rating and set a $17.00 price objective on the stock in a research report on Thursday, September 24th. Wall Street Zen raised Afya from a “hold” rating to a “buy” rating in a research report on Saturday, September 5th. Zacks Research raised Afya from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Weiss Ratings downgraded Afya from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. upgraded Afya from a “neutral” rating to an “overweight” rating and dropped their target price for the company from $21.00 to $19.00 in a report on Wednesday, October 7th. Two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $17.25.

Afya Price Performance

Shares of AFYA stock opened at $10.64 on Tuesday. The company has a market capitalization of $997.18 million, a PE ratio of 6.49, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. The firm has a fifty day simple moving average of $13.96 and a 200-day simple moving average of $14.31. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.39. Afya has a twelve month low of $10.05 and a twelve month high of $16.16.

Afya (NASDAQ:AFYA) last released its quarterly earnings results on Friday, August 14th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. Afya had a net margin of 20.55% and a return on equity of 17.58%. The business had revenue of $187.80 million during the quarter, compared to analyst estimates of $189.62 million. Equities research analysts anticipate that Afya will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Afya

In related news, insider Santos Welder Ferreira sold 4,161 shares of Afya stock in a transaction on Monday, October 5th. The shares were sold at an average price of $13.30, for a total transaction of $55,341.30. Following the transaction, the insider owned 35,000 shares in the company, valued at approximately $465,500. The trade was a 10.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Afya stock. Engineers Gate Manager LP purchased a new stake in Afya Limited (NASDAQ:AFYA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,882 shares of the company’s stock, valued at approximately $325,000. Institutional investors own 88.02% of the company’s stock.

About Afya

Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.

Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.

The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.